Padden Juliet, Megger Dominik A, Bracht Thilo, Reis Henning, Ahrens Maike, Kohl Michael, Eisenacher Martin, Schlaak Jörg F, Canbay Ali E, Weber Frank, Hoffmann Andreas-Claudius, Kuhlmann Katja, Meyer Helmut E, Baba Hideo A, Sitek Barbara
From the ‡Medizinisches Proteom-Center, Ruhr-Universität Bochum, 44801 Bochum, Germany;
¶Institut für Pathologie, Universitätsklinikum Essen, Universität Duisburg-Essen, 45141 Essen, Germany;
Mol Cell Proteomics. 2014 Oct;13(10):2661-72. doi: 10.1074/mcp.M113.034942. Epub 2014 Jul 17.
The aim of this study was the identification of novel biomarker candidates for the diagnosis of cholangiocellular carcinoma (CCC) and its immunohistochemical differentiation from benign liver and bile duct cells. CCC is a primary cancer that arises from the epithelial cells of bile ducts and is characterized by high mortality rates due to its late clinical presentation and limited treatment options. Tumorous tissue and adjacent non-tumorous liver tissue from eight CCC patients were analyzed by means of two-dimensional differential in-gel electrophoresis and mass-spectrometry-based label-free proteomics. After data analysis and statistical evaluation of the proteins found to be differentially regulated between the two experimental groups (fold change ≥ 1.5; p value ≤ 0.05), 14 candidate proteins were chosen for determination of the cell-type-specific expression profile via immunohistochemistry in a cohort of 14 patients. This confirmed the significant up-regulation of serpin H1, 14-3-3 protein sigma, and stress-induced phosphoprotein 1 in tumorous cholangiocytes relative to normal hepatocytes and non-tumorous cholangiocytes, whereas some proteins were detectable specifically in hepatocytes. Because stress-induced phosphoprotein 1 exhibited both sensitivity and specificity of 100%, an immunohistochemical verification examining tissue sections of 60 CCC patients was performed. This resulted in a specificity of 98% and a sensitivity of 64%. We therefore conclude that this protein should be considered as a potential diagnostic biomarker for CCC in an immunohistochemical application, possibly in combination with other candidates from this study in the form of a biomarker panel. This could improve the differential diagnosis of CCC and benign bile duct diseases, as well as metastatic malignancies in the liver.
本研究的目的是鉴定用于诊断胆管细胞癌(CCC)及其与良性肝和胆管细胞进行免疫组化鉴别的新型生物标志物候选物。CCC是一种起源于胆管上皮细胞的原发性癌症,因其临床症状出现较晚且治疗选择有限而具有高死亡率。通过二维差异凝胶电泳和基于质谱的无标记蛋白质组学对8例CCC患者的肿瘤组织和相邻的非肿瘤肝组织进行了分析。在对两个实验组之间差异调节的蛋白质进行数据分析和统计评估后(倍数变化≥1.5;p值≤0.05),选择了14种候选蛋白质,通过免疫组化在14例患者队列中确定细胞类型特异性表达谱。这证实了丝氨酸蛋白酶抑制剂H1、14-3-3蛋白σ和应激诱导磷蛋白1在肿瘤胆管细胞中相对于正常肝细胞和非肿瘤胆管细胞有显著上调,而有些蛋白质在肝细胞中可特异性检测到。由于应激诱导磷蛋白1表现出100%的敏感性和特异性,因此对60例CCC患者的组织切片进行了免疫组化验证检查。结果显示特异性为98%,敏感性为64%。因此,我们得出结论,在免疫组化应用中,该蛋白应被视为CCC的潜在诊断生物标志物,可能与本研究中的其他候选物以生物标志物组合的形式联合使用。这可以改善CCC与良性胆管疾病以及肝脏转移性恶性肿瘤的鉴别诊断。